2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

2084 A phase 3, randomized, double-blind, placebo-controlled study of oral roxadustat for anemia in lower-risk myelodysplastic syndrome with high red blood cell transfusion burden

Amer M. Zeidan, MD, Cynthia Wetmore, MD, PhD2, Jianjun Liu3, Andrew Grigston4, Mairead Carney5, Carrie Brownstein, MD6, Moshe Mittelman, MD7
1 Yale University, New Haven, Connecticut, United States
2 SSI Strategy/Kyntra Bio, San Diego, California, United States
3 Kyntra Bio, San Diego, California, United States
4 Kyntra Bio, San Diego, California, United States
5 Kyntra Bio, San Diego, California, United States
6 SSI Strategy/Kyntra Bio, San Diego, California, United States
7 Tel Aviv University, Tel Aviv, Israel

Background and Significance 

Patients with lower-risk myelodysplastic syndrome (MDS) and high red blood cell transfusion burden (HTB) face substantial morbidity. Currently available therapies remain limited to clinic-based parenteral administration and benefit only 35-50% of patients, leaving a considerable unmet need for effective, convenient oral treatment options. 

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stimulates coordinated erythropoiesis and improves iron mobilization. It is approved in more than 40 countries for anemia in chronic kidney disease. The prior Phase 3 MATTERHORN MDS study enrolled a high number of patients with low transfusion burden, contributing to a high rate of 8-week RBC transfusion independence (RBC-TI) of 33% in the placebo cohort. Although the response rate was higher with roxadustat than placebo (48% vs. 33%), the difference was not statistically significant. A post-hoc analysis of the HTB subgroup showed a nominally significant higher RBC-TI with roxadustat versus placebo at 8-weeks (36% vs 7%), and a meaningful trend of 12-week (27% vs. 7%) and 16-week RBC-TI (14% vs. 0%), providing the rationale for a dedicated trial in this population.  

Study Design and Methods 

FGCL-4592-115 is a global phase 3, randomized, double-blind, placebo-controlled multicenter study (NCT NCT07722988). Two-hundred one adult participants with LR-MDS with anemia and HTB will be randomized 2:1 (roxadustat:placebo), stratified by RBC transfusion burden, ring sideroblast status and IPSS-R risk category. A planned interim analysis, allowing for conditional power-based sample size re-estimation, will occur after 102 patients are enrolled and have completed 24 weeks of treatment. Efficacy will be assessed by stratified Cochran-Mantel-Haenszel testing at 1-sided alpha=0.025. The planned sample size will have at least 90% power to detect a difference in response rate in the experimental arm (roxadustat) compared to the control arm (placebo) in 8-week RBC-TI in the first 24 weeks. 

Population 

Adults 18 years old with IPSS-R very low, low, or intermediate risk MDS HTB.  

Key inclusion criteria: 

Confirmed MDS with < 5% bone marrow blasts  IPSS-R very low, low, or intermediate risk  High transfusion burden per IWG2018 (>4 and <10 RBC units in each of 2 consecutive 8-week periods prior to randomization)  Hemoglobin less than 10 g/dL  Serum EPO less than 500 IU/L  Refractory to, intolerant of, or ineligible for ESA therapy  May have had prior TGFb directed therapy  

Key exclusion criteria: 

MDS with del(5q) or secondary MDS  Prior stem cell transplant  Prior therapy with lenalidomide, imetelstat or hypomethylating agents  Unresolved thrombophilia or recent major cardiovascular/thromboembolic events  NYHA Class III/IV heart failure 

Treatment 

Roxadustat oral tablets 3 times weekly based upon weight band dosing with up titration as per predefined criteria.  

Endpoints 

Primary: Proportion of participants achieving >8 weeks of RBC transfusion independence (RBC-TI) during weeks 1-24. 

Key secondary: >12-week, >16-week and >24-week RBC-TI during weeks 1-48; minor hematologic improvement-erythroid (HI-E) response per IWG 2018 criteria through week 48. 

Exploratory: Patient reported outcomes including QLQ-C30, FACIT‑Fatigue and healthcare resource utilization.  

Study Duration 

The study comprises a 16-week pre-screening observation (prospective or retrospective) to document baseline transfusion burden for eligibility and randomization, an up to 35-day screening period, a 48-week double-blind treatment period, and an optional extension of the double-blind treatment period for those participants deriving clinical benefit. Enrollment of the first participants is expected early in 2027. Participants are in long-term follow-up for up to 3 years. 

Key Features and Oversight 

This study is focused on LR-MDS with HTB population, which is supported by post hoc analysis of the MATTERHORN study in which the HTB subgroup demonstrated differential clinically meaningful benefit. The study advances a novel oral agent based on a first-in-class mechanism of action (HIF-PH inhibition), offering at-home dosing as an alternative to clinic-based parenteral therapies. This patient-centric, scientifically rigorous design aims to address a well-defined unmet need with a convenient, orally administered therapeutic option. Global, multicenter execution ensures broad, representative enrollment across diverse regions. 

Amer M. Zeidan, MD: AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony); AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony)